Arkolith/Insider Trading/CTNM/Form 4

Stengone Carmine N.

CEO and President, DirectorContineum Therapeutics, Inc. (CTNM) · full profile →Form 4 · filed Jul 8, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$40K
Net Open-Market Flow
-$40K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 8, 2026Option exercise(M)3K$1.01$3K20K
Jul 8, 2026Sell(S)3K$16.00$40K17K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 8, 2026Option exercise(M)3K—$0279K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-047710) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML